Many younger patients with stomach cancer have a distinct …
Dec 17, 2019 · ROCHESTER, Minn. — Many people under 60 who develop stomach cancer have a "genetically and clinically distinct" disease, new Mayo Clinic research has discovered.
New heated drug baths provide hope for patients with stomach cancer
Apr 4, 2024 · Mayo Clinic researchers used a new approach to chemotherapy to more than double the typical survival rate for patients with stomach cancer and peritoneal metastasis, which is cancer that has spread to the lining of the abdominal cavity.
New Gastric & Esophageal Cancer Treatment Breakthrough
Mar 23, 2022 · There are new, FDA-authorized treatment options for people facing esophageal and gastric (stomach) cancer, thanks to clinical trials at Memorial Sloan Kettering that combined immunotherapy with standard treatments.
Clinical trials confirm zolbetuximab's efficacy in gastric cancer
6 days ago · In this research, treatment with zolbetuximab and chemotherapy significantly reduced the risk of disease progression and death by 29 percent. All participants in the trials had gastric cancer with ...
Metastatic Stomach Cancer: New Treatment to Be Approved - Healthline
Nov 28, 2023 · Zolbetuximab is a new drug for treating advanced gastric cancer. The FDA is expected to make an approval decision in January 2024.
Targeted treatment shows promise for stomach cancer
Aug 24, 2023 · An international phase 3 clinical trial found that a new targeted treatment, given in combination with a standard chemotherapy, extended survival for select patients with advanced gastric or gastroesophageal junction cancer.
FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer
April 16, 2021. Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or...
Phase 3 INTEGRATE IIa Study Supports Regorafenib as a New …
Oct 9, 2024 · Phase 3 INTEGRATE IIa Study Supports Regorafenib as a New Treatment Option for Refractory AGOC. Key Points: Single-agent regorafenib extends overall survival in patients with advanced gastric and oesophago-gastric junction cancer (AGOC) refractory to standard chemotherapy. The 1-year survival rate was 19% for regorafenib versus 6% for placebo.
Expert Alert: What’s new in gastric cancer treatment and research
Nov 17, 2021 · Gastric cancer, also known as stomach cancer, was the sixth most common cancer in 2020, with 1.09 million new cases, according to the World Health Organization. It was the fifth most common cause of cancer death in 2020. Gastric cancer is common in certain parts of the world, including South America and Asia.
Removing Stomach to Prevent Cancer Has Lasting Consequences
Jan 12, 2024 · People who carry one of the dangerous CDH1 variants have around a 40% chance of developing stomach cancer over their lifetime, according to Dr. Davis—although some studies have pegged that number to be as high as 80%.